Also, increased expression of Flot-2 is associated with poor outcomes in patients with several solid tumors, such as breast cancer, gastric cancer and cervical carcinoma, and Flot-2 could be used as a prognostic biomarker for these tumors progression [11–13]. Here, FLOT2 is linked to breast carcinoma.